Stryker SG&A increased by 2.4% to $2.28B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 0.8%, from $2.30B to $2.28B. Over 4 years (FY 2021 to FY 2025), SG&A shows an upward trend with a 7.7% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Increases may indicate aggressive marketing or expansion, while decreases often reflect cost-cutting measures or improved corporate efficiency.
The sum of all direct and indirect selling expenses and all general and administrative expenses of a company. This inclu...
Used to assess the 'leaness' of a company's corporate structure relative to its peers.
selling_general_and_administrative| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.51B | $1.60B | $1.75B | $1.71B | $1.54B | $1.46B | $1.75B | $1.78B | $1.71B | $1.70B | $1.94B | $1.84B | $1.85B | $1.90B | $2.10B | $2.30B | $2.08B | $2.05B | $2.23B | $2.28B |
| QoQ Change | — | +6.4% | +8.9% | -2.0% | -10.0% | -5.5% | +20.3% | +1.7% | -4.2% | -0.3% | +14.1% | -5.2% | +0.4% | +2.7% | +10.9% | +9.4% | -9.6% | -1.6% | +8.9% | +2.4% |
| YoY Change | — | — | — | — | +2.3% | -9.2% | +0.3% | +4.2% | +10.9% | +16.9% | +10.9% | +3.3% | +8.3% | +11.5% | +8.3% | +25.0% | +12.6% | +7.9% | +5.9% | -0.8% |
| Segment | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|
| MedSurg and Neurotechnology: | $937.00M | $984.00M | $972.00M | $1.04B | $930.00M |
| Total | $2.30B | $2.08B | $2.05B | $2.23B | $2.28B |